Peter Buggisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Buggisch has a total of 326 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Mauss
Center for HIV and Hepatogastroenterology Düsseldorf Germany
13 shared publications - Thomas Berg
Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
10 shared publications - Christoph Eisenbach
Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany
7 shared publications - Stefan Zeuzem
Department of Medicine, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
7 shared publications Dietrich Hüppe
Gastroenterologische Gemeinschaftspraxis Herne
6 shared publicationsGerlinde Teuber
Hepatologische Praxis, Frankfurt, Germany
6 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (8)
Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study
Background: Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective. Patients: We analysed blood samples of 507 patients recruited within the Fatty Liver Assessment in Germany (FLAG) study, of whom 476 (255 males, age 56 years) were genotyped. FLAG is a multicenter real‐world MASLD cohort covering secondary and tertiary healthcare levels. The PNPLA3 p.I148M and the HSD17B13 rs72613567 polymorphisms were genotyped using allelic discrimination assays. The control cohort comprised 174 individuals. Results: The PNPLA3 p.I148M variant was prevalent among FLAG patients ( p < 0.001 for the departure from Hardy–Weinberg equilibrium) and increased the risk of developing MASLD (common OR = 2.46, p = 6.238e‐09). It was associated with increased ALT and AST, lower serum triglyceride concentrations, and independently with liver stiffness ≥ 9.1 kPa after adjustment for BMI and diabetes (OR = 2.57, p = 0.01). Carriers of the HSD17B13 rs72613567 variant had lower AST. HSD17B13 heterozygotes had lower FIB‐4 ( p = 0.028) and lower liver stiffness ( p = 0.034). Among carriers of the PNPLA3 p.148M allele, the presence of the HSD17B13 variant was associated with lower ALT ( p = 0.023) and AST ( p = 0.041); however, HSD17B13 did not abrogate the association of PNPLA3 with liver fibrosis (adjusted p = 0.013). Discussion: By analysing a real‐world MASLD cohort in Germany, we further underscore the role of the PNPLA3 variant as the central genetic trigger and modulator of MASLD. The HSD17B13 polymorphism may exert protective effects in MASLD and could attenuate some PNPLA3 ‐associated effects.
- 7 October 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (8)
Open AccessMetabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study
Background: Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective. Patients: We analysed blood samples of 507 patients recruited within the Fatty Liver Assessment in Germany (FLAG) study, of whom 476 (255 males, age 56 years) were genotyped. FLAG is a multicenter real‐world MASLD cohort covering secondary and tertiary healthcare levels. The PNPLA3 p.I148M and the HSD17B13 rs72613567 polymorphisms were genotyped using allelic discrimination assays. The control cohort comprised 174 individuals. Results: The PNPLA3 p.I148M variant was prevalent among FLAG patients ( p < 0.001 for the departure from Hardy–Weinberg equilibrium) and increased the risk of developing MASLD (common OR = 2.46, p = 6.238e‐09). It was associated with increased ALT and AST, lower serum triglyceride concentrations, and independently with liver stiffness ≥ 9.1 kPa after adjustment for BMI and diabetes (OR = 2.57, p = 0.01). Carriers of the HSD17B13 rs72613567 variant had lower AST. HSD17B13 heterozygotes had lower FIB‐4 ( p = 0.028) and lower liver stiffness ( p = 0.034). Among carriers of the PNPLA3 p.148M allele, the presence of the HSD17B13 variant was associated with lower ALT ( p = 0.023) and AST ( p = 0.041); however, HSD17B13 did not abrogate the association of PNPLA3 with liver fibrosis (adjusted p = 0.013). Discussion: By analysing a real‐world MASLD cohort in Germany, we further underscore the role of the PNPLA3 variant as the central genetic trigger and modulator of MASLD. The HSD17B13 polymorphism may exert protective effects in MASLD and could attenuate some PNPLA3 ‐associated effects.
- Open Access
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Healthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Open AccessHealthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- Open Access
- 15 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (4) , 414
Health-Related Quality of Life in Previous Versus Current Opiate Users Receiving HCV Therapy: Registry-Based Evidence
Background: Health and social outcomes of previous opiate users (POUs) are not well-documented. We characterize the life situation, health status, and health-related quality of life (HRQoL) of POUs entering antiviral hepatitis C (HCV) treatment, compared with HCV patients without past illicit opiate use (NOU), and with HCV patients currently in opiate agonist treatment (OAT). Methods: Data are taken from the German Hepatitis C-Registry (“Deutsches Hepatitis C-Register”, DHCR), a multi-centre registry study focussing on the course and outcome of HCV treatment with directly acting antivirals. At treatment entry, patients underwent a standardized clinical assessment, including the Short Form 36 (SF-36) for self-reported HRQoL. Results: POUs (n = 734) and OAT patients (n = 554) were similar with regard to age, sex, migrant background, and psychiatric comorbidity. Employment rate and cannabis, alcohol, and smoking abstinence rates were higher for POUs than for OAT patients, but still lower than for NOU (n = 4147) patients. Mental and physical HRQoL was better for POUs than for OAT patients, but worse than for NOU patients. Compared with SF-36 normative data, POUs showed decreased HRQoL, especially regarding mental health. Conclusions: Compared with opiate-dependent patients in OAT, POUs showed less psychotropic substance use and better HRQoL. Compared with NOU patients and the general population, mental health problems were especially increased. Challenges persist for POUs even during abstinence from opiates, highlighting the need for targeted interventions tailored to the specific needs of this population.
- 15 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (4) , 414
Open AccessHealth-Related Quality of Life in Previous Versus Current Opiate Users Receiving HCV Therapy: Registry-Based Evidence
Background: Health and social outcomes of previous opiate users (POUs) are not well-documented. We characterize the life situation, health status, and health-related quality of life (HRQoL) of POUs entering antiviral hepatitis C (HCV) treatment, compared with HCV patients without past illicit opiate use (NOU), and with HCV patients currently in opiate agonist treatment (OAT). Methods: Data are taken from the German Hepatitis C-Registry (“Deutsches Hepatitis C-Register”, DHCR), a multi-centre registry study focussing on the course and outcome of HCV treatment with directly acting antivirals. At treatment entry, patients underwent a standardized clinical assessment, including the Short Form 36 (SF-36) for self-reported HRQoL. Results: POUs (n = 734) and OAT patients (n = 554) were similar with regard to age, sex, migrant background, and psychiatric comorbidity. Employment rate and cannabis, alcohol, and smoking abstinence rates were higher for POUs than for OAT patients, but still lower than for NOU (n = 4147) patients. Mental and physical HRQoL was better for POUs than for OAT patients, but worse than for NOU patients. Compared with SF-36 normative data, POUs showed decreased HRQoL, especially regarding mental health. Conclusions: Compared with opiate-dependent patients in OAT, POUs showed less psychotropic substance use and better HRQoL. Compared with NOU patients and the general population, mental health problems were especially increased. Challenges persist for POUs even during abstinence from opiates, highlighting the need for targeted interventions tailored to the specific needs of this population.
- Open Access
- 24 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1140-1153
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
INTRODUCTION: The objective of these analyses was to evaluate interim data from the ongoing, open-label, long-term efficacy and safety ASSURE study of seladelpar, a selective peroxisome proliferator-activated receptor δ agonist, in primary biliary cholangitis. METHODS: Patients rolling over from the phase 3, randomized, placebo-controlled, 12-month RESPONSE study or with previous participation in earlier legacy seladelpar studies were enrolled. Interim evaluations included composite biochemical response (alkaline phosphatase <1.67 upper limit of normal, total bilirubin ≤ upper limit of normal, and alkaline phosphatase decrease ≥15%), pruritus numerical rating scale (NRS) change among patients with a baseline score ≥4, and safety. RESULTS: At interim cutoff, 337 patients were enrolled and received ≥1 seladelpar 10 mg dose: 54 placebo-treated and 104 seladelpar-treated from RESPONSE and 179 from legacy studies. The composite response rate at RESPONSE completion was 62% (79/128) with seladelpar and 20% (13/65) with placebo. After 12 months in ASSURE, among patients who rolled over from RESPONSE, response rates were 72% (21/29) in patients continuing seladelpar and 94% (15/16) in crossover seladelpar patients. In legacy trial patients, response rates were 73% (120/164) and 70% (69/99) after 12 and 24 months of treatment in ASSURE, respectively. The NRS decrease at RESPONSE completion in seladelpar-treated patients with baseline NRS ≥4 (−3.4) was maintained after 6 additional months of treatment (−3.8); changes were similar in crossover seladelpar (−3.8) and legacy patients (−3.5) after 6 months of treatment in ASSURE. No seladelpar-related serious adverse events were reported. DISCUSSION: Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.
- 24 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1140-1153
Open AccessLong-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
INTRODUCTION: The objective of these analyses was to evaluate interim data from the ongoing, open-label, long-term efficacy and safety ASSURE study of seladelpar, a selective peroxisome proliferator-activated receptor δ agonist, in primary biliary cholangitis. METHODS: Patients rolling over from the phase 3, randomized, placebo-controlled, 12-month RESPONSE study or with previous participation in earlier legacy seladelpar studies were enrolled. Interim evaluations included composite biochemical response (alkaline phosphatase <1.67 upper limit of normal, total bilirubin ≤ upper limit of normal, and alkaline phosphatase decrease ≥15%), pruritus numerical rating scale (NRS) change among patients with a baseline score ≥4, and safety. RESULTS: At interim cutoff, 337 patients were enrolled and received ≥1 seladelpar 10 mg dose: 54 placebo-treated and 104 seladelpar-treated from RESPONSE and 179 from legacy studies. The composite response rate at RESPONSE completion was 62% (79/128) with seladelpar and 20% (13/65) with placebo. After 12 months in ASSURE, among patients who rolled over from RESPONSE, response rates were 72% (21/29) in patients continuing seladelpar and 94% (15/16) in crossover seladelpar patients. In legacy trial patients, response rates were 73% (120/164) and 70% (69/99) after 12 and 24 months of treatment in ASSURE, respectively. The NRS decrease at RESPONSE completion in seladelpar-treated patients with baseline NRS ≥4 (−3.4) was maintained after 6 additional months of treatment (−3.8); changes were similar in crossover seladelpar (−3.8) and legacy patients (−3.5) after 6 months of treatment in ASSURE. No seladelpar-related serious adverse events were reported. DISCUSSION: Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.
- 11 August 2023
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 61 (08) , e446-e447
TRISTAN – a Secondary Use of Data (SUD), retrospective real world data acquisition for therapy management of Wilson Disease Patients in Germany
Introduction Wilson disease (WD) is a rare autosomal recessively inherited disorder of copper metabolism with pathological copper accumulation mainly in the liver and brain. Chelators are mainly used as treatment for WD. In Germany D-penicillamine is approved as first-line treatment and Trientine (Trientine dihydrochloride (TETA-2HCl) and Trientine tetrahydrochloride (TETA-4HCL)), is available for patients who are intolerant to D-penicillamine. Data on therapy management of patients, specifically with respect to treatment switch and dosing, is rare. Aim This secondary use of data (SUD) project aims to assess retrospective real-world data regarding the diagnostic and therapeutic management, duration, sequence, and dosing of the different therapeutic options in specialized WD centres in Germany. Method In this project, anonymized data from WD patients who received Trientine therapy at least once during their course of treatment in the period of 1.01.2012 and 31.12.2021 and had one or more documented follow-up visits will be included. During the observation period D-Penicillamine, Zinc and two formulations of Trientine (TETA-2HCl and TETA-4HCl) were available. We aim to include 6 German WD centers and up to 150 patients. A questionnaire will be used to capture centre structure, WD diagnoses and therapeutic standards. Additionally, a second questionnaire will collect data for each suitable patient regarding the disease and therapy history. This includes all previous and the current treatments, switching between therapies, the duration of the treatments as well as the duration of the de-coppering phase and the maintenance phase. Furthermore, the dosage of said therapies during de-coppering and maintenance phase will be provided. Results The obtained data will be analysed using exploratory analysis (descriptive analysis/graphical display) based on the various aspects of the treatment management of WD patients. This includes demographic values as well as the number of treatment sequences, dosages prescribed during the different sequences and comparing the de-coppering and maintenance phase. Furthermore, a possible influence of the demographic factors and symptomatic classifications on therapy management will be investigated. Conclusion This project will contribute to a better understanding of the therapy management of WD patients in German specialized WD centres and might support physicians in future therapy decisions. Article published online: 28 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 11 August 2023
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 61 (08) , e446-e447
TRISTAN – a Secondary Use of Data (SUD), retrospective real world data acquisition for therapy management of Wilson Disease Patients in Germany
Introduction Wilson disease (WD) is a rare autosomal recessively inherited disorder of copper metabolism with pathological copper accumulation mainly in the liver and brain. Chelators are mainly used as treatment for WD. In Germany D-penicillamine is approved as first-line treatment and Trientine (Trientine dihydrochloride (TETA-2HCl) and Trientine tetrahydrochloride (TETA-4HCL)), is available for patients who are intolerant to D-penicillamine. Data on therapy management of patients, specifically with respect to treatment switch and dosing, is rare. Aim This secondary use of data (SUD) project aims to assess retrospective real-world data regarding the diagnostic and therapeutic management, duration, sequence, and dosing of the different therapeutic options in specialized WD centres in Germany. Method In this project, anonymized data from WD patients who received Trientine therapy at least once during their course of treatment in the period of 1.01.2012 and 31.12.2021 and had one or more documented follow-up visits will be included. During the observation period D-Penicillamine, Zinc and two formulations of Trientine (TETA-2HCl and TETA-4HCl) were available. We aim to include 6 German WD centers and up to 150 patients. A questionnaire will be used to capture centre structure, WD diagnoses and therapeutic standards. Additionally, a second questionnaire will collect data for each suitable patient regarding the disease and therapy history. This includes all previous and the current treatments, switching between therapies, the duration of the treatments as well as the duration of the de-coppering phase and the maintenance phase. Furthermore, the dosage of said therapies during de-coppering and maintenance phase will be provided. Results The obtained data will be analysed using exploratory analysis (descriptive analysis/graphical display) based on the various aspects of the treatment management of WD patients. This includes demographic values as well as the number of treatment sequences, dosages prescribed during the different sequences and comparing the de-coppering and maintenance phase. Furthermore, a possible influence of the demographic factors and symptomatic classifications on therapy management will be investigated. Conclusion This project will contribute to a better understanding of the therapy management of WD patients in German specialized WD centres and might support physicians in future therapy decisions. Article published online: 28 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 September 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 292, 766-772
Influence of gender on cytokine induced depression and treatment
- 1 September 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 292, 766-772
Influence of gender on cytokine induced depression and treatment
- Open Access
- 10 May 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (5) , e0250833
Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
Despite the availability of highly effective and well-tolerated direct-acting antivirals, not all patients with chronic hepatitis C virus infection receive treatment. This retrospective, multi-centre, noninterventional, case-control study identified patients with chronic hepatitis C virus infection initiating (control) or not initiating (case) treatment at 43 sites in Germany from September 2017 to June 2018. It aimed to compare characteristics of the two patient populations and to identify factors involved in patient/physician decision to initiate/not initiate chronic hepatitis C virus treatment, with a particular focus on historical barriers. Overall, 793 patients were identified: 573 (72%) who received treatment and 220 (28%) who did not. In 42% of patients, the reason for not initiating treatment was patient wish, particularly due to fear of treatment (17%) or adverse events (13%). Other frequently observed reasons for not initiating treatment were in accordance with known historical barriers for physicians to initiate therapy, including perceived or expected lack of compliance (14.5%), high patient age (10.9%), comorbidities (15.0%), alcohol abuse (9.1%), hard drug use (7.7%), and opioid substitution therapy (4.5%). Patient wish against therapy was also a frequently reported reason for not initiating treatment in the postponed (35.2%) and not planned (47.0%) subgroups; of note, known historical factors were also common reasons for postponing treatment. Real-world and clinical trial evidence is accumulating, which suggests that such historical barriers do not negatively impact treatment effectiveness. Improved education is key to facilitate progress towards the World Health Organization target of eliminating viral hepatitis as a major public health threat by 2030.
- 10 May 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (5) , e0250833
Open AccessBarriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
Despite the availability of highly effective and well-tolerated direct-acting antivirals, not all patients with chronic hepatitis C virus infection receive treatment. This retrospective, multi-centre, noninterventional, case-control study identified patients with chronic hepatitis C virus infection initiating (control) or not initiating (case) treatment at 43 sites in Germany from September 2017 to June 2018. It aimed to compare characteristics of the two patient populations and to identify factors involved in patient/physician decision to initiate/not initiate chronic hepatitis C virus treatment, with a particular focus on historical barriers. Overall, 793 patients were identified: 573 (72%) who received treatment and 220 (28%) who did not. In 42% of patients, the reason for not initiating treatment was patient wish, particularly due to fear of treatment (17%) or adverse events (13%). Other frequently observed reasons for not initiating treatment were in accordance with known historical barriers for physicians to initiate therapy, including perceived or expected lack of compliance (14.5%), high patient age (10.9%), comorbidities (15.0%), alcohol abuse (9.1%), hard drug use (7.7%), and opioid substitution therapy (4.5%). Patient wish against therapy was also a frequently reported reason for not initiating treatment in the postponed (35.2%) and not planned (47.0%) subgroups; of note, known historical factors were also common reasons for postponing treatment. Real-world and clinical trial evidence is accumulating, which suggests that such historical barriers do not negatively impact treatment effectiveness. Improved education is key to facilitate progress towards the World Health Organization target of eliminating viral hepatitis as a major public health threat by 2030.
- Open Access
- 2 December 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (12) , 2101
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection
Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral therapy indication. The aim of this study was to prospectively assess the utility of point shear wave elastography (pSWE) for longitudinal non-invasive fibrosis assessment in a large cohort of untreated patients with chronic HBeAg-negative hepatitis B virus (HBV) infection. Methods: 407 consecutive patients with HBeAg-negative HBV infection who underwent pSWE, transient elastography (TE) as well as laboratory fibrosis markers, including fibrosis index based on four factors (FIB-4), aspartate to platelet ratio index (APRI) and FibroTest, on the same day were prospectively followed up for six years. Patients were classified into one of the three groups: inactive carriers (IC; HBV-DNA 2000 IU/mL and ALT p < 0.001) and APRI (r = 0.17; p = 0.005). Median pSWE values did not differ between IC, GZ-1 and GZ-2 patients (p = 0.82, p = 0.17, p = 0.34). During six years of follow-up, median pSWE and TE values did not differ significantly over time (TE: p = 0.27; pSWE: p = 0.05). Conclusion: Our data indicate that pSWE could be useful for non-invasive fibrosis assessment and follow-up in patients with HBeAg-negative chronic HBV infection.
- 2 December 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (12) , 2101
Open AccessEvaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection
Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral therapy indication. The aim of this study was to prospectively assess the utility of point shear wave elastography (pSWE) for longitudinal non-invasive fibrosis assessment in a large cohort of untreated patients with chronic HBeAg-negative hepatitis B virus (HBV) infection. Methods: 407 consecutive patients with HBeAg-negative HBV infection who underwent pSWE, transient elastography (TE) as well as laboratory fibrosis markers, including fibrosis index based on four factors (FIB-4), aspartate to platelet ratio index (APRI) and FibroTest, on the same day were prospectively followed up for six years. Patients were classified into one of the three groups: inactive carriers (IC; HBV-DNA 2000 IU/mL and ALT p < 0.001) and APRI (r = 0.17; p = 0.005). Median pSWE values did not differ between IC, GZ-1 and GZ-2 patients (p = 0.82, p = 0.17, p = 0.34). During six years of follow-up, median pSWE and TE values did not differ significantly over time (TE: p = 0.27; pSWE: p = 0.05). Conclusion: Our data indicate that pSWE could be useful for non-invasive fibrosis assessment and follow-up in patients with HBeAg-negative chronic HBV infection.
- Open Access
- 4 April 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (4) , e0214795
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
Newer direct-acting antiviral therapies are increasingly becoming the therapy of choice in patients with hepatitis C virus (HCV) infection. Here, we report the safety and effectiveness of sofosbuvir/velpatasvir (SOF/VEL) and ledipasvir/sofosbuvir (LDV/SOF) in real-world cohorts in Germany. Patients initiated on SOF/VEL 12 weeks or LDV/SOF 8, 12 or 24 weeks regimens in a single German centre were included in this study. Data on treatment outcomes and adverse events (AE) were analysed in patients with available sustained virologic response 12 weeks after cessation of treatment (SVR12) information overall and by subgroups. This study included 115 patients who received SOF/VEL from July-2016 to July-2017, and 249 patients who received LDV/SOF from November-2014 to September-2015. Overall, SVR12 was achieved in 99% of patients on SOF/VEL ± ribavirin 12 weeks independent of HCV genotype, treatment history, or cirrhosis status, and in 96% of patients treated with LDV/SOF 8 weeks or LDV/SOF ± ribavirin 12 or 24 weeks. In genotype 1 treatment-naïve, non-cirrhotic patients, ≥99% achieved SVR12 across SOF/VEL and LDV/SOF regimens. Likewise, 100% of genotype 3-cirrhotic patients on SOF/VEL ± ribavirin regimens achieved SVR12. Grade 3/4 AE were reported in 13 (5.2%) patients on LDV/SOF and in 1 (<1%) patient on SOF/VEL. Overall, SOF/VEL and LDV/SOF achieved high SVR rates in a broad patient population. We showed the effectiveness of SOF/VEL as a pan-genotypic regimen, and regardless of treatment history or cirrhosis status. Use of such therapies improves outcomes and contributes towards the global efforts to eradicate HCV.
- 4 April 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (4) , e0214795
Open AccessReal-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
Newer direct-acting antiviral therapies are increasingly becoming the therapy of choice in patients with hepatitis C virus (HCV) infection. Here, we report the safety and effectiveness of sofosbuvir/velpatasvir (SOF/VEL) and ledipasvir/sofosbuvir (LDV/SOF) in real-world cohorts in Germany. Patients initiated on SOF/VEL 12 weeks or LDV/SOF 8, 12 or 24 weeks regimens in a single German centre were included in this study. Data on treatment outcomes and adverse events (AE) were analysed in patients with available sustained virologic response 12 weeks after cessation of treatment (SVR12) information overall and by subgroups. This study included 115 patients who received SOF/VEL from July-2016 to July-2017, and 249 patients who received LDV/SOF from November-2014 to September-2015. Overall, SVR12 was achieved in 99% of patients on SOF/VEL ± ribavirin 12 weeks independent of HCV genotype, treatment history, or cirrhosis status, and in 96% of patients treated with LDV/SOF 8 weeks or LDV/SOF ± ribavirin 12 or 24 weeks. In genotype 1 treatment-naïve, non-cirrhotic patients, ≥99% achieved SVR12 across SOF/VEL and LDV/SOF regimens. Likewise, 100% of genotype 3-cirrhotic patients on SOF/VEL ± ribavirin regimens achieved SVR12. Grade 3/4 AE were reported in 13 (5.2%) patients on LDV/SOF and in 1 (<1%) patient on SOF/VEL. Overall, SOF/VEL and LDV/SOF achieved high SVR rates in a broad patient population. We showed the effectiveness of SOF/VEL as a pan-genotypic regimen, and regardless of treatment history or cirrhosis status. Use of such therapies improves outcomes and contributes towards the global efforts to eradicate HCV.
- Open Access
- 18 January 2019
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 28 (6) , 15-26
Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
Ингибитор протеазы Телапревир (ТПВ) является одним из первых противовирусных препаратов прямого действия (ПППД) и применялся в странах Евросоюза при лечении хронического гепатита С в качестве нового метода с сентября 2011 года по сентябрь 2016 года. Цель: Оценить применение правил остановки (прекращения) или сокращения периода терапии и их влияние на устойчивый вирусологический ответ (УВО), а также безопасность и эффективность противовирусной терапии на основе ТПВ при рутинном применении в Германии. Материалы и методы. В неинтервенционном мультицентровом исследовании участвовали 802 пациента (272 пациента, ранее не получавшие, и 520 пациентов, ранее получавшие противовирусные препараты). Результаты. Устойчивый вирусологический ответ (УВО) был достигнут у 56,6 % пациентов. Доля пациентов с УВО среди пациентов с рецидивом после предыдущего лечения была выше (68,0 %), чем у пациентов с предыдущим нулевым ответом (31,1 %) и у пациентов, ранее не получавших противовирусные препараты (58,1 %). Критериям прекращения терапии соответствовали 3,2 % пациентов, из них у 65,4 % лечение было остановлено. Критериям сокращения терапии соответствовали 34,3 % пациентов. Это правило было применено в отношении 48,4 % из них, у 34,5 % оно не соблюдалось. Таким образом, не всегда соблюдались рекомендации по прекращению или сокращению терапии. Чаще терапию сокращали в группе пациентов, ранее не получавших лечения (54,8%), чем в группе пациентов, получавших противовирусную терапию в анамнезе (24,2%). Именно применение правил прекращения терапии, а не сокращение ее продолжительности, позволило снизить затраты на лечение. Заключение. Терапия на основе ТПВ в свое время стала прорывом в лечении гепатита С. Позже были предложены новые варианты ПППД для терапии, что усложнило выбор и точность применения препаратов. ПППД привнесли одновременно как новые возможности, так и новые сложности.
- 18 January 2019
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 28 (6) , 15-26
Open AccessReal-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
Ингибитор протеазы Телапревир (ТПВ) является одним из первых противовирусных препаратов прямого действия (ПППД) и применялся в странах Евросоюза при лечении хронического гепатита С в качестве нового метода с сентября 2011 года по сентябрь 2016 года. Цель: Оценить применение правил остановки (прекращения) или сокращения периода терапии и их влияние на устойчивый вирусологический ответ (УВО), а также безопасность и эффективность противовирусной терапии на основе ТПВ при рутинном применении в Германии. Материалы и методы. В неинтервенционном мультицентровом исследовании участвовали 802 пациента (272 пациента, ранее не получавшие, и 520 пациентов, ранее получавшие противовирусные препараты). Результаты. Устойчивый вирусологический ответ (УВО) был достигнут у 56,6 % пациентов. Доля пациентов с УВО среди пациентов с рецидивом после предыдущего лечения была выше (68,0 %), чем у пациентов с предыдущим нулевым ответом (31,1 %) и у пациентов, ранее не получавших противовирусные препараты (58,1 %). Критериям прекращения терапии соответствовали 3,2 % пациентов, из них у 65,4 % лечение было остановлено. Критериям сокращения терапии соответствовали 34,3 % пациентов. Это правило было применено в отношении 48,4 % из них, у 34,5 % оно не соблюдалось. Таким образом, не всегда соблюдались рекомендации по прекращению или сокращению терапии. Чаще терапию сокращали в группе пациентов, ранее не получавших лечения (54,8%), чем в группе пациентов, получавших противовирусную терапию в анамнезе (24,2%). Именно применение правил прекращения терапии, а не сокращение ее продолжительности, позволило снизить затраты на лечение. Заключение. Терапия на основе ТПВ в свое время стала прорывом в лечении гепатита С. Позже были предложены новые варианты ПППД для терапии, что усложнило выбор и точность применения препаратов. ПППД привнесли одновременно как новые возможности, так и новые сложности.